ArticleJournal of molecular histology2025
CSF2RA promotes gastric cancer progression through activation of the JAK2/STAT3 signaling pathway.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudoautosomal regions (PARs), located at the ends of sex chromosomes, harbor genes that may play a role in tumor pathology by regulating cell proliferation and the immune microenvironment. Gastric cancer (GC) is a prevalent and molecularly heterogeneous malignancy of the digestive system. However, studies on the role of PARs-related genes in GC are limited. This study focuses on the PARs gene CSF2RA and its regulatory role in GC progression through the JAK2/STAT3 signaling pathway. Differentially expressed PARs-related genes associated with GC were identified using multi-omics datasets(including TCGA-STAD and four GEO cohorts). Functional enrichment, immune infiltration, and drug sensitivity analyses, combined with in vitro (using MKN45 and AGS cell lines) and in vivo experiments, were conducted to validate the role of CSF2RA in GC. Additionally, RT-qPCR, Western blot, immunofluorescence, and co-immunoprecipitation assays were performed to investigate the interaction between CSF2RA and JAK2 and their activation of downstream signaling pathways. CSF2RA was found to be highly expressed in GC and associated with poor prognosis. It was significantly enriched in the JAK/STAT signaling pathway and closely related to immune cell infiltration. Furthermore, CSF2RA promoted GC cell proliferation and metastasis by activating the JAK2/STAT3 pathway. The JAK inhibitor Ruxolitinib effectively reversed the tumor-promoting effects of CSF2RA and demonstrated significant inhibitory effects in both in vitro and in vivo experiments. This study is the first to reveal the tumor-promoting mechanism of CSF2RA in GC, demonstrating its role in facilitating tumor progression via the JAK2/STAT3 signaling pathway. The potential therapeutic value of Ruxolitinib was validated in both cell-based and xenograft tumor models. Future research should further explore the upstream regulatory mechanisms of CSF2RA and its dynamic role in the immune microenvironment to advance precision treatment strategies for GC.
Indexed as
Identifiers
40913748What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.